The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBlackRock Smaller Companies Trust PLC Regulatory News (BRSC)

Share Price Information for BlackRock Smaller Companies Trust PLC (BRSC)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,442.00
Bid: 1,440.00
Ask: 1,442.00
Change: 0.00 (0.00%)
Spread: 2.00 (0.139%)
Open: 1,430.00
High: 1,442.00
Low: 1,430.00
Prev. Close: 1,442.00
BRSC Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Portfolio Update

20 Sep 2016 16:50

BLACKROCK SMALLER COMPANIES TRUST PLC - Portfolio Update

BLACKROCK SMALLER COMPANIES TRUST PLC - Portfolio Update

PR Newswire

London, September 20

BLACKROCK SMALLER COMPANIES TRUST PLC All information is at 31 August 2016 and unaudited.
Performance at month end is calculated on a capital only basis
OneThreeOneThreeFive
monthmonthsyearyearsyears
%%%%%
Net asset value*5.02.13.733.795.1
Share price*6.0-1.6-3.221.388.1
Numis ex Inv Companies + AIM (capital only)3.43.02.111.444.7
*performance calculations based on a capital only NAV with debt at par, without income reinvested. Share price performance calculations exclude income reinvestment.
Sources: BlackRock and Datastream
At month end
Net asset value Capital only(debt at par value):1,064.58p
Net asset value Capital only(debt at fair value):1,055.00p
Net asset value incl. Income(debt at par value)**:1,079.29p
Net asset value incl. Income(debt at fair value)**:1,069.71p
Share price895.50p
Discount to Cum Income NAV (debt at par value):17.0%
Discount to Cum Income NAV (debt at fair value):16.3%
Net yield^^^:1.95%
Gross assets^:£551.7m
Gearing range as a % of net assets:0-15%
Net gearing including income (debt at par):6.9%
2016 Ongoing charges ratio^^0.7%
2016 Ongoing charges ratio (including performance fees):0.9%
Ordinary shares in issue#:47,879,792
**includes net revenue of 14.71p ^includes current year revenue ^^ As reported in the Annual Financial Report for the year ended 29 February 2016, the ongoing charges ratio is calculated as a percentage of net assets and using operating expenses, excluding performance fees, finance costs and taxation. ^^^Yield calculations are based on dividends announced in the last 12 months as at the date of release of this announcement, and comprise of the final dividend of 10.50 pence per share, (announced on 25 April 2016, ex-dividend on 19 May 2016) and the interim dividend of 7.00 pence per share (announced on 26 October 2015 and gone ex-dividend on 5 November 2015) #excludes 2,113,731 shares held in treasury.
Sector Weightings% of portfolio
Industrials 29.1
Consumer Services 20.3
Financials13.8
Technology9.9
Consumer Goods9.0
Basic Materials8.1
Health Care7.7
Oil & Gas1.9
Utilities0.2
-----
Total100.0
=====

Ten Largest Equity Investments
Company% of portfolio
4imprint Group2.7
CVS Group2.4
Fevertree Drinks2.0
Dechra Pharmaceuticals1.9
Hill & Smith1.8
Advanced Medical Solutions1.7
Restore1.7
GB Group1.6
Savills1.5
Accesso Technology1.4
Commenting on the markets, Mike Prentis, representing the Investment Manager noted: During August the Company’s NAV per share rose by 5.0% on a capital only basis whilst our benchmark index, the Numis ex Inv Companies + AIM (capital only), rose by 3.4%; the FTSE 100 Index rose by 0.8%. Outperformance was largely driven by stock selection with our large holdings in 4imprint Group and CVS Group contributing well. 4imprint announced half year results which showed revenues up 17%, all organic, 19% increase in earnings per share and net cash of $20m. 96% of 4imprint Group’s revenue is generated in the USA. Trading patterns in the first half are expected to continue into the second half. CVS Group put out a year end trading update which indicated results were expected to be modestly ahead of market expectations. Like-for-like revenues were up 4.8% for the year to 30 June, up from a more normal 3.0% in the first half. CVS Group has continued to be acquisitive adding 67 surgeries in the year taking its total surgeries operated to 360. There were no holdings which were significant detractors from relative performance from a stock specific point of view during the month. Gearing added modestly to relative performance. Sector allocation made a small position contribution with our overweight position in housing related stocks helping. During the month we added a number of small holdings including Ultra Electronics, Coats, Dairy Crest and Costain. Ultra and Coats both generate the majority of their revenues internationally. Ultra is more confident of seeing a return to organic sales growth and defence budgets are generally looking better underpinned. Coats is benefitting from the growth of the Asian consumer, although it is a truly global business. Dairy Crest should benefit from higher cheese profits and the growth of its demineralised whey business. Costain should benefit from increasing infrastructure spending. 20 September 2016 ENDS Latest information is available by typing www.blackrock.co.uk/brsc on the internet, "BLRKINDEX" on Reuters, "BLRK" on Bloomberg or "8800" on Topic 3 (ICV terminal). Neither the contents of the Manager’s website nor the contents of any website accessible from hyperlinks on the Manager’s website (or any other website) is incorporated into, or forms part of, this announcement.
Date   Source Headline
2nd Jan 202412:21 pmPRNNet Asset Value(s)
29th Dec 202312:14 pmPRNNet Asset Value(s)
28th Dec 202312:19 pmPRNNet Asset Value(s)
27th Dec 202312:05 pmPRNNet Asset Value(s)
27th Dec 20237:00 amPRNTotal Voting Rights
22nd Dec 202312:03 pmPRNNet Asset Value(s)
21st Dec 20235:54 pmPRNTransaction in Own Shares
21st Dec 20235:09 pmPRNPortfolio Update
21st Dec 202311:44 amPRNNet Asset Value(s)
20th Dec 202312:15 pmPRNNet Asset Value(s)
19th Dec 202311:59 amPRNNet Asset Value(s)
18th Dec 202312:10 pmPRNNet Asset Value(s)
15th Dec 202311:58 amPRNNet Asset Value(s)
14th Dec 202312:37 pmPRNNet Asset Value(s)
13th Dec 202311:06 amPRNNet Asset Value(s)
12th Dec 202311:46 amPRNNet Asset Value(s)
11th Dec 20234:32 pmPRNHolding(s) in Company
11th Dec 202311:56 amPRNNet Asset Value(s)
8th Dec 20231:03 pmPRNNet Asset Value(s)
7th Dec 202312:43 pmPRNNet Asset Value(s)
6th Dec 202311:16 amPRNNet Asset Value(s)
5th Dec 20235:41 pmPRNHolding(s) in Company
5th Dec 202311:20 amPRNNet Asset Value(s)
4th Dec 202312:01 pmPRNNet Asset Value(s)
1st Dec 20235:15 pmPRNTotal Voting Rights
1st Dec 20235:14 pmPRNHolding(s) in Company
1st Dec 202312:11 pmPRNNet Asset Value(s)
30th Nov 202312:03 pmPRNNet Asset Value(s)
29th Nov 202311:42 amPRNNet Asset Value(s)
28th Nov 202311:40 amPRNNet Asset Value(s)
27th Nov 202311:18 amPRNNet Asset Value(s)
24th Nov 202312:03 pmPRNNet Asset Value(s)
23rd Nov 20234:33 pmPRNPortfolio Update
23rd Nov 202311:55 amPRNNet Asset Value(s)
22nd Nov 202311:28 amPRNNet Asset Value(s)
21st Nov 202311:42 amPRNNet Asset Value(s)
20th Nov 202311:37 amPRNNet Asset Value(s)
17th Nov 202311:56 amPRNNet Asset Value(s)
16th Nov 202311:47 amPRNNet Asset Value(s)
15th Nov 202311:25 amPRNNet Asset Value(s)
14th Nov 202312:15 pmPRNNet Asset Value(s)
14th Nov 202311:54 amPRNHolding(s) in Company
13th Nov 202311:16 amPRNNet Asset Value(s)
10th Nov 202311:26 amPRNNet Asset Value(s)
9th Nov 20236:30 pmPRNSubmission of Documents
9th Nov 202311:23 amPRNNet Asset Value(s)
8th Nov 202311:14 amPRNNet Asset Value(s)
7th Nov 202311:12 amPRNNet Asset Value(s)
6th Nov 202311:47 amPRNNet Asset Value(s)
3rd Nov 202312:01 pmPRNNet Asset Value(s)

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.